이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Lipigon Pharmaceuticals 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Stefan Nilsson

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	8.5yrs
CEO 소유권	1.5%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	2.8yrs

최근 관리 업데이트

Recent updates

CEO

Stefan Nilsson (45 yo)

8.5yrs

테뉴어

Dr. Stefan K. Nilsson serves as the Chief Executive Officer of Lipigon Pharmaceuticals AB since 2016. Dr. Nilsson is an entrepreneur and Co-Founder of Lipigon. Dr. Nilsson has been central in all Lipigon’s...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Lars Öhman	Business Development Manager & Chairman	12.5yrs	데이터 없음	0.27% SEK 89.2k
Fredrik Lindgren	Director	less than a year	데이터 없음	데이터 없음
Jessica Martinsson	Independent Director	3.2yrs	데이터 없음	0.13% SEK 42.9k
David Westberg	Independent Director	1.5yrs	데이터 없음	0.024% SEK 7.8k
Johannes Hulthe	Director	3.5yrs	데이터 없음	0.16% SEK 52.0k
Maj Hedtjarn	Scientific Advisor	no data	데이터 없음	데이터 없음
Ludger Scheja	Scientific Advisor	no data	데이터 없음	데이터 없음
Sander Kersten	Scientific Advisor	no data	데이터 없음	데이터 없음
Troels Koch	Scientific Advisor	no data	데이터 없음	데이터 없음
Jorg Heeren	Scientific Advisor	no data	데이터 없음	데이터 없음
Eva Lindqvist	Independent Director	2.5yrs	데이터 없음	0.71% SEK 234.0k

2.8yrs

평균 재임 기간

57.5yo

평균 연령

경험이 풍부한 이사회: LPGO 의 이사회는 경험(평균 재직 기간 2.8 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Lipigon Pharmaceuticals 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Co-Founder & CEO recently bought kr101k worth of stock

Co-Founder & CEO recently bought kr135k worth of stock

Business Development Manager & Chairman exercised options to buy kr146k worth of stock.

Co-Founder & CEO recently bought kr68k worth of stock

Less than half of directors are independent

No independent directors

Recent updates

Co-Founder & CEO recently bought kr101k worth of stock

The Swedish Medical Products Agency Approves Lipigon's Phase II Study with Lipisense

Co-Founder & CEO recently bought kr135k worth of stock

Business Development Manager & Chairman exercised options to buy kr146k worth of stock.

Lipigon Pharmaceuticals AB (Publ) Announces Lipisense Progressing to Phase II Trials

Lipigon Pharmaceuticals AB (Publ) Reports A Statically Confirms reduction of target protein ANGPTL4 after repeate treatment with Lipisense ®

Lipigon Applies for Clinical Trial Phase II for Lipisense

New major risk - Revenue and earnings growth

Co-Founder & CEO recently bought kr68k worth of stock

Lipigon Pharmaceuticals AB (publ) Announces Positive Safety Results and Encouraging Target Engagement Data from the Phase I Lipisense Trial

Lipigon Announces Further Positive Data from Phase I Trial of Lipisense

Third quarter 2022 earnings released: kr0.36 loss per share (vs kr1.18 loss in 3Q 2021)

Less than half of directors are independent

Lipigon Pharmaceuticals AB (publ) Announces Positive Top-Line Data from Phase I Clinical Study of Lipisense

Lipigon Pharmaceuticals AB (Publ) Announces Liver-Specific Treatment of Target Protein ANGPTL4 Is Effective and Safe

Lipigon Pharmaceuticals AB Announces First-In-Human Phase I Trial with Lipigon's Lipid-Lowering Candidate Lipisense

Lipigon Receives CTA Approval for Lipid-Lowering Candidate Lipisense

No independent directors

Lipigon Pharmaceuticals AB Confirms Patent Application for Drug Candidate Lipisense in US

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Lipigon Pharmaceuticals AB (publ) Ready to Apply for Clinical Trials After Successful Completion of Preclinical Safety Studies

Lipigon Pharmaceuticals AB (Publ) Completes Another Preclinical Study with Drug Candidate Lipisense

Lipigon Announces Positive Results from Preclinical Study for Lipid-Lowering Drug Candidate Lipisense

Third quarter 2021 earnings: Revenues in line with analyst expectations

Lipigon Expands Collaboration with Hitgen by Selecting Second Target

CEO

테뉴어

이사회 구성원

평균 재임 기간

평균 연령